MOUNTAIN VIEW, Calif.
July 15, 2013
/PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended
June 30, 2013
Thursday, August 8, 2013
, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at
5:00 p.m. Eastern Time
2:00 p.m. Pacific Time
to provide a company update and discuss the financial results.
To access the conference call and webcast via the Internet, go to
, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register at
To access the live conference call, dial 888-713-4205 (domestic) or +1-617-213-4862 (international). The reference number to enter the call is 17723266.
The replay of the conference call may be accessed at
under the "Investor Relations" link, or by dialing 888-286-8010 (domestic) or +1-617-801-6888 (international). The reference number for the replay of the call is 27674002. A replay of the call will be available for 30 days following the event.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions, including agitation, acute repetitive seizures and insomnia. Alexza's products are based on the Staccato
system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner.
loxapine), Alexza's first approved product, was approved by the U.S. Food and Drug Administration in
and by the European Medicines Agency in February 2013. Teva Pharmaceutical
, Inc. is Alexza's commercial partner for ADASUVE in the U.S.
Grupo Ferrer Internacional
, S.A. is Alexza's commercial partner for ADASUVE in
and the Commonwealth of Independent States countries.
For more information about Alexza, the
system technology or the Company's development programs, please visit
. For more information about ADASUVE, please visit
are registered trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
The anticipated news release and conference call will contain
forward-looking statements that involve significant risks and uncertainties.
Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the ability of Alexza and our partners, Teva and Ferrer, to effectively and profitably commercialize ADASUVE,
estimated product revenues and royalties associated with the sale of ADASUVE, the adequacy of the Company's capital to support the Company's operations, and the Company's ability to raise additional funds and the potential terms of such potential financings. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2012 and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.